Most material SEC filings — October 20, 2026

On June 28, 2026, Iridium Communications Inc. entered into a Merger Agreement with Rocket Lab Corporation whereby Rocket Lab will acquire Iridium. The company has issued retention award agreements to key employees with vesting tranches: 60% payable at closing, 40% at six-month post-closing anniversary, or 100% if the merger is terminated by June 28, 2027. Specific dollar amounts are redacted in this template agreement; individual award values are not disclosed.

XWELL, Inc. (market cap ~$3.6M) received notice of delisting failure or continued listing rule violation on 2026-10-07, triggering Item 3.01 filing on 2026-10-20. No specific remediation plan, timeline, or exchange communication details disclosed in this 8-K stub.

On September 30, 2026, Peoples Bancorp (PEBO, ~$1.0B market cap) announced a definitive merger agreement to acquire Capital Bancorp, Inc. (Rockville, Maryland) in an all-stock transaction valued at approximately $728.1 million. Capital Bank, N.A. will merge into Peoples Bank. As of quarter-end, $1.0 million in acquisition-related expenses had been recognized. Separately, Peoples also announced on April 21, 2026 a pending cash-and-stock acquisition of Citizens National Corporation (Paintsville, Kentucky) for ~$76.6 million.

Rapport Therapeutics announced positive topline results from a Phase 2 trial of RAP-219 in 253 adults with acute bipolar mania (253 enrolled, 126 RAP-219 vs. 127 placebo). The trial met its primary endpoint with a statistically significant 3.1-point placebo-adjusted improvement in YMRS total score at Week 3 (p=0.045; RAP-219 mean reduction 15.4 points vs. placebo 12.3 points) and secondary endpoint with 0.4-point CGI-BP mania severity improvement (p=0.024). RAP-219 was well-tolerated with all TEAEs mild/moderate, 3.2% discontinuation due to AEs (vs. 0.8% placebo), and notably absent the somnolence, akathisia, and extrapyramidal symptoms typical of current bipolar drugs. The company plans an End-of-Phase 2 FDA meeting in Q1 2027 and Phase 3 initiation in H2 2027.

GE Aerospace reported Q3 2026 orders of $19.0B (+49%), revenue of $14.1B GAAP (+16%), and adjusted EPS of $2.25 (+36%). The company raised full-year 2026 guidance: adjusted revenue to $42.3B (~19-20% growth, up from prior high-teens), operating profit to $10.9–$11.0B (up from $10.55–$10.75B), and adjusted EPS to $8.00–$8.10 (up from $7.65–$7.85). Key drivers include Commercial Engines & Services orders up 58% and year-to-date engine deliveries up 20%; announced $2.9B multi-year F414 defense contract; agreed to acquire Consolidated Precision Products (CPP) for castings capacity; and signed ~1,800 engine commitments at Farnborough (including 1,000+ LEAP-1A with IndiGo and 300+ LEAP-1B with Turkish Airlines).

Hasbro reported Q3 2026 revenue of $1,595.3M (+15% YoY), with Magic: The Gathering surpassing $600M quarterly revenue for the first time (+34% YoY). The company raised 2026 guidance to 7-9% revenue growth (from 5-7%) and 27-28% adjusted operating margin (from 25-26%), and doubled its share repurchase target. Monopoly Go! contributed $41M in Q3 revenue; year-to-date it generated $127M. Adjusted EPS was $2.90 for Q3 and $5.65 YTD.

Odyssey announced completed Phase 2a induction results for OD-001 (oral RIPK2 scaffolding inhibitor) in 56 moderate-to-severe ulcerative colitis patients. At 20 mg BID (n=41), clinical remission was 27%, clinical response 61%, symptomatic remission 49%, with significant reductions in inflammatory biomarkers (hsCRP, neutrophils) and favorable safety (no SAEs, serious infections, or drug-related discontinuations). Transcriptomic analyses confirmed on-target RIPK2 pathway inhibition. Company advancing OD-001 into Phase 2b monotherapy and Phase 2a vedolizumab combination trials with topline results expected H2 2027.

Iridium completed its acquisition of Aireon (space-based ADS-B air traffic surveillance) on July 2, 2026, generating a $103.9M gain in Q3. Separately, stockholders approved Rocket Lab's acquisition of Iridium on September 24, 2026 with 99.6% approval (81.4% of shares voting), expected to close mid-2027 pending regulatory approvals. Q3 revenue grew 8% YoY to $245.7M; service revenue up 13% YoY, primarily from Aireon contribution.

Vicor reported Q3 2026 revenues of $197.1M (78.5% YoY growth, 37.5% sequential), with gross margin expanding to 68.3% and net income of $63.3M ($1.33 diluted EPS). Backlog reached $406M (up 166% YoY from $153M). CEO announced purchase of two additional manufacturing sites near ChiP Fab-1 for ~5X capacity expansion, granted first VPD license to AI OEM at Stage-2 royalty rates, and noted ITC investigation into VPD infringement prompting competitor license inquiries. Cash increased to $513.1M; nine-month 2026 revenues reached $453.4M.

AIB Data Centers (total assets ~$90.4M) signed a 12-year colocation agreement with Nebius Inc. for 50 MW of critical IT capacity at CLT1, with two 5-year renewal options. The company has secured ~120 MW of contracted utility power across five named sites (CLT1: 65 MW, Texas: 55 MW). CLT1 phases are expected to deliver in Q4 2027. Portfolio projects $6.56B total contract value over 12-year terms across all five sites, with customer prepayments expected to fund development alongside project-level debt and preferred equity.

United Community Banks completed three major strategic actions in Q3 2026: (1) sold Navitas equipment finance business for $2.0 billion in cash (7% premium to par), generating $145 bps CET1 capital benefit; (2) reclassified $2.2 billion HTM securities to AFS and sold $2.5 billion low-yielding securities, reinvesting $4.1 billion total proceeds into higher-yielding securities and repaying ~$1 billion borrowings; (3) acquired Peach State Bancshares for complementary growth, adding $520M loans and $678M deposits. Core loan growth was 9.8% annualized ($444M), core deposits grew 8.0% annualized ($473M). GAAP EPS was $(1.16) reflecting $366M securities loss and $62M Navitas gain; operating EPS $0.77. Net interest margin stable at 3.68%.

RTX reported Q3 2026 sales of $25.0B (+11% YoY, +12% organic), adjusted EPS of $2.26 (+33% YoY), and free cash flow of $2.1B. The company raised full-year 2026 guidance: adjusted sales to $97.0–$97.5B (from $95.0–$96.0B), organic growth to 10–11% (from 8–9%), adjusted EPS to $7.65–$7.75 (from $7.10–$7.25), and free cash flow to $9.0–$9.2B (from $8.50–$8.75B). Backlog reached a record $340B ($176B commercial, $164B defense), with $81B in new awards in Q3.